The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Symptom O
intensity O
was O
measured O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
score O
range O
, O
0 O
- O
900 O
) O
. O

Hazard O
ratios O
( O
HRs O
) O
for O
comparing O
thalidomide O
against O
placebo O
were O
estimated O
using O
Cox O
regression O
modeling O
. O

As O
well O
, O
Etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3 I-Claim
- I-Claim
drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
MEV I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPC I-Claim
. I-Claim

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti I-Claim
- I-Claim
TNF I-Claim
therapy I-Claim
. I-Claim

Suggestions O
for O
future O
studies O
include O
the O
use O
of O
three O
- O
group O
designs O
( O
e O
. O
g O
. O
, O
comparing O
two O
active O
interventions O
with O
a O
standard O
- O
care O
control O
) O
and O
examining O
mechanisms O
of O
change O
. O

Four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
PE I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
for I-Claim
extensive I-Claim
- I-Claim
stage I-Claim
SCLC I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim

One O
thousand O
eighty O
- O
eight O
women O
were O
randomly O
allocated O
to O
sentinel O
- O
lymph O
- O
node O
biopsy O
followed O
by O
axillary O
clearance O
if O
the O
sentinel O
node O
was O
positive O
or O
not O
detected O
( O
SNBM O
) O
or O
routine O
axillary O
clearance O
( O
RAC O
, O
sentinel O
- O
lymph O
- O
node O
biopsy O
followed O
immediately O
by O
axillary O
clearance O
) O
. O

The B-Premise
use I-Premise
of I-Premise
IMRT I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise

Progression B-Premise
- B-Premise
free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1 I-Premise
. I-Premise
07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
92 I-Premise
to I-Premise
1 I-Premise
. I-Premise
24 I-Premise
) I-Premise
. I-Premise

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Randomisation O
was O
done O
in O
blocks O
of O
12 O
- O
20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer O
- O
generated O
sequence O
. O

The O
exercise O
group O
followed O
a O
progressive O
, O
8 O
- O
week O
upper O
- O
body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
Monark O
Rehab O
Trainer O
arm O
ergometer O
. O

The O
fat O
content O
of O
the O
artificial O
diet O
was O
66 O
% O
of O
the O
nonprotein O
calories O
. O

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1 I-Premise
\/ I-Premise
G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
more I-Premise
than I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

No B-Premise
relevant I-Premise
differences I-Premise
in I-Premise
adverse I-Premise
effects I-Premise
were I-Premise
observed I-Premise
among I-Premise
the I-Premise
groups I-Premise
during I-Premise
either I-Premise
the I-Premise
titration I-Premise
phase I-Premise
and I-Premise
chronic I-Premise
treatment I-Premise
. I-Premise

WHO B-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
diarrhoea I-Premise
affected I-Premise
46 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CPT I-Premise
- I-Premise
11 I-Premise
+ I-Premise
LFA I-Premise
5 I-Premise
- I-Premise
FU I-Premise
. I-Premise

Despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
GJJ B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long I-Claim
- I-Claim
term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim

Adjusted B-Premise
linear I-Premise
mixed I-Premise
- I-Premise
model I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
, I-Premise
at I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
the I-Premise
RET I-Premise
group I-Premise
reported I-Premise
higher I-Premise
self I-Premise
- I-Premise
esteem I-Premise
[ I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1 I-Premise
. I-Premise
6 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
, I-Premise
0 I-Premise
. I-Premise
1 I-Premise
- I-Premise
3 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
032 I-Premise
] I-Premise
and I-Premise
the I-Premise
AET I-Premise
group I-Premise
reported I-Premise
lower I-Premise
anxiety I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
- I-Premise
4 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
9 I-Premise
. I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
049 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

Alternating B-Claim
chemotherapy I-Claim
with I-Claim
PAV I-Claim
- I-Claim
CyMOC I-Claim
plus I-Claim
consolidating I-Claim
radiotherapy I-Claim
is I-Claim
a I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
with I-Claim
acceptable I-Claim
toxicity I-Claim
. I-Claim

The B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Impaired B-Claim
cognition I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
diminished I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
are I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

Improvement B-Claim
over I-Claim
time I-Claim
was I-Claim
evident I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
but I-Claim
more I-Claim
so I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
placebo I-Claim
. I-Claim

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post I-Claim
- I-Claim
treatment I-Claim
. I-Claim

